News coverage about Transcat (NASDAQ:TRNS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Transcat earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news stories about the scientific and technical instruments company an impact score of 47.580474421365 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Transcat (TRNS) remained flat at $12.90 during mid-day trading on Monday. 8 shares of the company’s stock were exchanged. Transcat has a 52 week low of $9.99 and a 52 week high of $14.05. The stock has a market cap of $91.96 million, a price-to-earnings ratio of 20.48 and a beta of 0.34. The stock has a 50-day moving average of $12.65 and a 200 day moving average of $12.15.

Transcat (NASDAQ:TRNS) last released its quarterly earnings results on Tuesday, July 25th. The scientific and technical instruments company reported $0.12 earnings per share for the quarter. Transcat had a return on equity of 10.37% and a net margin of 3.03%. The company had revenue of $36.28 million for the quarter. Equities analysts expect that Transcat will post $0.64 EPS for the current fiscal year.

In other Transcat news, Director Paul D. Moore sold 4,000 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $13.00, for a total value of $52,000.00. Following the sale, the director now owns 57,698 shares in the company, valued at $750,074. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Carl E. Sassano sold 7,500 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $13.02, for a total value of $97,650.00. Following the completion of the sale, the director now owns 79,075 shares in the company, valued at approximately $1,029,556.50. The disclosure for this sale can be found here. Insiders have purchased a total of 2,081 shares of company stock worth $24,924 in the last 90 days. 8.80% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at

About Transcat

Transcat, Inc is a provider of calibration and laboratory instrument services and a distributor of professional grade test, measurement and control instrumentation. The Company conducts its business through two segments: service (Service) and distribution (Distribution). Through the Service segment, the Company offers calibration, repair, inspection, analytical qualifications, preventative maintenance and other related services, a majority of which are processed through its asset management system, CalTrak (CalTrak).

Insider Buying and Selling by Quarter for Transcat (NASDAQ:TRNS)

Receive News & Ratings for Transcat Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.